Illumina Looks To Clinical Consumables And China Restart To Offset Intensifying NGS Price Pressure

Sequencing Group Works To Rebuild China Funnel While Instruments Remain A Drag And Pricing Pressure Rises Globally.

 
• By Shubham Singh
  
Illumina expects no material change in academic end markets next year, with mid- to high-single-digit revenue declines in research and applied consumables.

More from Strategy

More from Business